Ronald Buggage
About
In The Last Decade
Ronald Buggage
68 papers receiving 3.3k citations
Hit Papers
Peers
Comparison fields: 5 of 112
- Ophthalmology 2.2k
- Radiology, Nuclear Medicine and Imaging 1.2k
- Molecular Biology 543
- Neurology 396
- Pathology and Forensic Medicine 379
Countries citing papers authored by Ronald Buggage
This map shows the geographic impact of Ronald Buggage's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ronald Buggage with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ronald Buggage more than expected).
Fields of papers citing papers by Ronald Buggage
This network shows the impact of papers produced by Ronald Buggage. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ronald Buggage. The network helps show where Ronald Buggage may publish in the future.
Co-authorship network of co-authors of Ronald Buggage
This figure shows the co-authorship network connecting the top 25 collaborators of Ronald Buggage. A scholar is included among the top collaborators of Ronald Buggage based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ronald Buggage. Ronald Buggage is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | EYS606 for the Treatment of Chronic Non-Infectious Uveitis (NIU): Results from Part 1 of a First-in-Human (EYS606-CT1) study | 3 |
| 2 | 30 | |
| 3 | One Year Results of a Phase I/IIa Study of SAR422459 in Patients with Stargardt Macular Degeneration (SMD) | 8 |
| 4 | 3-Year Interim Safety Profile of Adeno-Associated Virus Serotype 2-soluble Variant of the Vascular Endothelial Growth Factor Receptor Type 1 (AAV2-sFLT01) Administered by Intravitreal Injection in Patients with Neovascular Age-Related Macular Degeneration | 2 |
| 5 | Early findings in a Phase I/IIa clinical program for Usher syndrome 1B (USH1B; MIM #276900) | 4 |
| 6 | 30 | |
| 7 | The Influence of Seasonality and Subtype in Vernal Keratoconjunctivitis (VKC) Patients in a Randomized Clinical Trial Investigating NOVA22007, a preservative-free cyclosporine cationic emulsion | 1 |
| 8 | 41 | |
| 9 | 62 | |
| 10 | Poor Correlation Between Dry Eye Disease (DED) Signs and Symptoms in a Phase III Randomized Clinical Trial | 10 |
| 11 | 1 | |
| 12 | 4 | |
| 13 | 32 | |
| 14 | Clinical Characteristics and Impact of Neovascular Age–Related Macular Degeneration on Medical Status, Daily Living, Functioning, and Health Resource Utilization: A Survey of Five Countries | 2 |
| 15 | 37 | |
| 16 | 13 | |
| 17 | 5 | |
| 18 | 23 | |
| 19 | 21 | |
| 20 | 41 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.